[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiayuan Sun\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100614245","the-percutaneous-interventional-surgery-control-system-for-pulmonary-nodule-biopsy-100614245",false,"NCT07277088","The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy","A Prospective, Single-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of the Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy","Inclusion Criteria:\n\n1\\) Age ranging from 18 years old to 80 years old, gender not restricted; 2) Patients with pulmonary nodules detected by chest CT, suspected to be malignant and judged by the researchers to require puncture biopsy for a clear diagnosis; 3) Pulmonary nodules with a long diameter greater than 8mm but not exceeding 30mm; 4) Have signed the informed consent form and voluntarily participate in this clinical study; 5) Can understand this research and cooperate with the research procedures, and can follow the requirements for follow-up observation.\n\nExclusion Criteria:\n\n1\\) Subjects with irreparable coagulation dysfunction, infectious lesions on the puncture path, lesions adjacent to organs or surrounded by large blood vessels, suspected pulmonary echinococcosis on imaging, patients on mechanical ventilation (with a ventilator), liver multilocular echinococcosis, coma or other patients who are uncooperative; 2) Those judged by the investigators to be unsuitable for chest percutaneous puncture surgery: such as severe pulmonary hypertension, pulmonary bullae, chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis; 3) Poor overall condition (multiple systemic metastases, severe infection, high fever), obvious cachexia, severe dysfunction of important organs, severe anemia and nutritional metabolic disorders that cannot be improved in the short term; 4) Those allergic to contrast agents or anesthetics; 5) Implantation of pacemakers; 6) Pregnant or lactating women, or those with a fertility plan during the clinical trial; 7) Patients who cannot cooperate with the doctor to complete the puncture surgery, such as known drug or alcohol addiction, mental and neurological diseases, intellectual disability, psychological disorders, etc.; 8) Those participating in another drug or medical device clinical trial (within 3 months of drug clinical trial or within 1 month of medical device clinical trial); 9) The target lesion has been diagnosed or has received treatment; 10) Other situations that the investigator deems not suitable for this clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},158,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, single-center, non-inferiority, randomized controlled clinical trial aims to evaluate the efficacy and safety of a percutaneous interventional surgical control system in performing percutaneous needle biopsy of pulmonary nodules, compared with conventional manual biopsy. The study will be conducted at Shanghai Chest Hospital and plans to enroll 158 patients who meet the indications for percutaneous transthoracic needle biopsy (PTNB) and have no contraindications. Participants will be randomly assigned to one of two groups: the experimental group will undergo PTNB assisted by the percutaneous interventional surgical control system, while the control group will receive traditional manual PTNB. The primary endpoint is diagnostic yield; secondary endpoints include technical success rate, number of needle adjustments, puncture time, total procedure time, radiation dose, and complication rates.",[27,28,29,30,31],"Pulmonary Nodules","Lung Cancer (Diagnosis)","Percutaneous Needle Biopsy","Transthoracic Needle Biopsy","Robotic Assisted Intervention",[29,30,27,28,31],"NOT_YET_RECRUITING","2025-11-30",{"date":36,"type":37},"2025-12-11","ACTUAL",{"date":39,"type":21},"2025-12-10",{"date":41,"type":21},"2027-05-30",{"name":43,"class":44},"Jiayuan Sun","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100560084","transthoracic-vs-transbronchial-cryoablation-for-early-stage-peripheral-lung-cancer-100560084","NCT06572540","Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer","Transthoracic Versus Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age older than 18 years.\n2. Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary).\n3. The target lesion was evaluated to be feasible for both CT and bronchoscopy-guided ablation.\n4. Patients who are not suitable for surgery or refuse surgery, agree to undergo initial ablation therapy and sign informed consent form.\n\nExclusion Criteria:\n\n1. Patients with platelets \\\u003C70×109\u002FL, severe bleeding tendency and coagulation dysfunction that cannot be corrected in a short term.\n2. Patients with severe pulmonary fibrosis and pulmonary arterial hypertension.\n3. Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever \\>38.5°C.\n4. Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in a short term.\n5. Those with poorly controlled malignant pleural effusions.\n6. Anticoagulation therapy and\u002For anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) have not been discontinued more than 5\\~7d before ablation.\n7. Eastern Cooperative Oncology Group (ECOG) score \\>2.\n8. Combination with other tumors with extensive metastases and an expected survival of \\\u003C6 months.\n9. Patients with episodic psychosis.\n10. Pregnant women, or patients with pregnancy plan during the study period.\n11. Have participated or are participating in other clinical studies within 30 days.\n12. Any other condition that the investigator considers inappropriate for participation in this study.",{"count":54,"type":21},110,[24],"The study aims to compare the efficacy and safety of transthoracic cryoablation to transbronchial cryoablation in the treatment of early-stage peripheral lung cancer.",[58],"Lung Cancer",[60,61,62,63],"Cryoablation","Lung cancer","Transbronchial ablation","Transthoracic ablation","RECRUITING","2025-07-15",{"date":67,"type":37},"2025-07-18",{"date":69,"type":37},"2024-09-01",{"date":71,"type":21},"2028-12-31",{"name":43,"class":44},5,""]